Real World Evidence (RWE)
![AI-ML-enabled-real-world-evidenceRWE-analytics-1](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/AI-ML-enabled-real-world-evidenceRWE-analytics-1.jpg?width=690&height=468&name=AI-ML-enabled-real-world-evidenceRWE-analytics-1.jpg)
AI/ML-enabled RWE analytics
Augment value for pharma and medical devices by analyzing real-world evidence (RWE) across the product life cycle.
Real-world evidence
RWE rises to support clinical inferences on treatment efficacies. The information from electronic health records (EHR) and electronic medical records (EMR) along with other patient treatment records is compelling to guide companies, physicians, and the managed care ecosystem to deliver truly benefitting patient outcomes. Razor-sharp data and analytics capabilities are crucial for harvesting real-world data (RWD) and delivering evidence-based assessments across the healthcare value continuum.
Axtria’s experience with RWE data management, along with its AI/ML RWE models help healthcare stakeholders generate and demonstrate value and meet growing evidence generation requirements.
AI-driven solution applications
![AI-driven-solution-applications-icon1-1](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/AI-driven-solution-applications-icon1-1.png?width=140&height=140&name=AI-driven-solution-applications-icon1-1.png)
AI/ML models to quantify the magnitude of misdiagnosed patients for targeted intervention.
![AI-driven-solution-applications-icon2-1](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/AI-driven-solution-applications-icon2-1.png?width=140&height=140&name=AI-driven-solution-applications-icon2-1.png)
New product insights into market access through patient sub-population model.
![AI-driven-solution-applications-icon3-1](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/AI-driven-solution-applications-icon3-1.png?width=140&height=140&name=AI-driven-solution-applications-icon3-1.png)
Identifying “biologic-ready” patients for better insights into the overall disease burden.
Drivers for evidence-based demonstrations across the product life cycle
Pre-launch
![Pre-launch-icon](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/Pre-launch-icon.png?width=88&height=88&name=Pre-launch-icon.png)
- Unmet needs and disease burden
- Patient recruitment
- Understand the standard of care
- Clinical trial design
Launch and scale
![Launch-and-Scale-icon](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/Launch-and-Scale-icon.png?width=88&height=88&name=Launch-and-Scale-icon.png)
- Patient safety
- Product comparative effectiveness
- Patient adherence
- Prescribing patterns
- Differentiation in sub-populations
- Long-term clinical outcomes
- Target population implications
Loss-of-exclusivity (LOE)
![Loss-of-exclusivity-icon](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/Loss-of-exclusivity-icon.png?width=88&height=88&name=Loss-of-exclusivity-icon.png)
- Effects of switching on outcomes
- Usage differences
- Differentiate with or vs. protected formulation
- For payers to deliver cost-effective care coverage and value for patients’ money.
- For providers to identify better ways to manage patient health.
- For life sciences organizations to make better decisions related to pre-launch, market access, and commercialization.
Axtria’s RWE/HEOR solutions span across the healthcare value spectrum
RWD Expertise
![RWD-EXPERTISE-Icon1](https://www.axtria.com/hs-fs/hubfs/axtria-new-images/RWD-EXPERTISE-Icon1.png?width=50&height=50&name=RWD-EXPERTISE-Icon1.png)
Patient claims
![RWD-EXPERTISE-Icon2](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWD-EXPERTISE-Icon2.png?width=50&height=50&name=RWD-EXPERTISE-Icon2.png)
EHR/EMR data
![RWD-EXPERTISE-Icon3](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWD-EXPERTISE-Icon3.png?width=50&height=50&name=RWD-EXPERTISE-Icon3.png)
Lab results
![RWD-EXPERTISE-Icon4](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWD-EXPERTISE-Icon4.png?width=50&height=50&name=RWD-EXPERTISE-Icon4.png)
Patient registries
![RWD-EXPERTISE-Icon5](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWD-EXPERTISE-Icon5.png?width=50&height=50&name=RWD-EXPERTISE-Icon5.png)
Adverse event reporting
![RWD-EXPERTISE-Icon6](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWD-EXPERTISE-Icon6.png?width=50&height=50&name=RWD-EXPERTISE-Icon6.png)
Patient-powered research networks (PPRN)
RWE/HEOR Applications Across Domains
![RWE-HEOR-APPLICATIONS-Icon1](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWE-HEOR-APPLICATIONS-Icon1.png?width=50&height=50&name=RWE-HEOR-APPLICATIONS-Icon1.png)
Study design
![RWE-HEOR-APPLICATIONS-Icon2](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWE-HEOR-APPLICATIONS-Icon2.png?width=50&height=50&name=RWE-HEOR-APPLICATIONS-Icon2.png)
Epidemiology analysis
![RWE-HEOR-APPLICATIONS-Icon3](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWE-HEOR-APPLICATIONS-Icon3.png?width=50&height=50&name=RWE-HEOR-APPLICATIONS-Icon3.png)
Real-world comparative analysis
![RWE-HEOR-APPLICATIONS-Icon4](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWE-HEOR-APPLICATIONS-Icon4.png?width=50&height=50&name=RWE-HEOR-APPLICATIONS-Icon4.png)
Patient compliance and persistence
![RWE-HEOR-APPLICATIONS-Icon5](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWE-HEOR-APPLICATIONS-Icon5.png?width=50&height=50&name=RWE-HEOR-APPLICATIONS-Icon5.png)
Market access and reimbursement strategy
![RWE-HEOR-APPLICATIONS-Icon6](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWE-HEOR-APPLICATIONS-Icon6.png?width=50&height=50&name=RWE-HEOR-APPLICATIONS-Icon6.png)
Biomarker analysis
![RWE-HEOR-APPLICATIONS-Icon7](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWE-HEOR-APPLICATIONS-Icon7.png?width=50&height=50&name=RWE-HEOR-APPLICATIONS-Icon7.png)
Burden of disease analysis
![RWE-HEOR-APPLICATIONS-Icon8](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWE-HEOR-APPLICATIONS-Icon8.png?width=50&height=50&name=RWE-HEOR-APPLICATIONS-Icon8.png)
Drug utilization and patient profiling
![RWE-HEOR-APPLICATIONS-Icon9](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWE-HEOR-APPLICATIONS-Icon9.png?width=50&height=50&name=RWE-HEOR-APPLICATIONS-Icon9.png)
Publication and HTA submission support
![RWE-HEOR-APPLICATIONS-Icon10](https://www.axtria.com/hs-fs/hubfs/Axtria-2023/solutions/RWE-HEOR-APPLICATIONS-Icon10.png?width=50&height=50&name=RWE-HEOR-APPLICATIONS-Icon10.png)
Budget impact analysis
Axtria research hub
![](https://www.axtria.com/hubfs/Risk%20Of%20Venous%20Thromboembolism%20And%20Major%20Bleeding%20In%20Patients%20With%20Acute%20Medical%20Illness%20Receiving%20Thromboprophylaxis%20With%20Enoxaparin.png)
Report
Risk Of Venous Thromboembolism And Major Bleeding In Patients With Acute Medical Illness Receiving Thromboprophylaxis With Enoxaparin
Customer success stories
![](https://www.axtria.com/hubfs/Axtria-2023/solutions/Axtria-Insights-CS-Automated-Email-Campaigns-Support-The-Patient-Assistance-Journey-For-Enhanced-Treatment-Outcomes%20%283%29.jpg)
Case Study